Chemesis International Inc. (CSE:CSI) is a cannabis company expanding its presence across newly compliant dispensaries across California. Having established their presence in the Golden State, the company is looking to expand their operations in Latin America, where the medicinal cannabis industry is growing.

In an interview with James West from Midas Letter, Chemesis CEO Edgar Montero provided an overview of the company’s operations in California, where the company has deployed its California Sap brand and has also acquired Desert Zen, a fully compliant manufacturing and distribution company. Montero also gave viewers insight into the current regulations in the Californian market, which set strict parameters for the distribution and sale of cannabis products. As dispensaries come online with regulations launched in July 1, 2018, Chemesis is building relationships with more of these.


In his interview, Montero also addressed the company’s Latin American expansion plans. From his perspective, the Latin American market is anticipating further legalization and growth, akin to that which we have seen in Canada and the US. Seeing the potential for the size of the market, Chemesis is looking into building relationships with existing actors in the cannabis space.

“Remember that Latin America, it’s a market itself, and you need to build a relationship,” he said. “You need to do your due diligence very properly, because it’s a market that requires a very tight relationship, and this is what we’re working on right now.”

Moving forward, the company is also focused on building shareholder value. This is tied to the company’s recent $25 million equity financing agreement with Alumina Partners, which Montero believes is a key milestone for Chemesis.

To watch the full interview, click here.

Click here to connect with Chemesis International Inc. (CSE:CSI) for an investor presentation.

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced the Company will have senior management participating in the following virtual financial community conferences and events during December 2020 .

  • Roth Deer Valley Consumer Conference – December 9 th to 11 th , 2020
  • Cantor Fitzgerald 2020 Virtual Cannabis MSO Summit – December 15 th to 16 th , 2020
  • MKM Partners – The Road Ahead, Preparation for 2021 Conference – December 15 th to 16 th , 2020

For more information regarding upcoming Curaleaf financial community conference and event participation please visit the investor relations section of the company website, under the events tab, at https://ir.curaleaf.com/events .

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less